Fax: (713) 794-4385
Prognostic value of P53, MDM-2, and MUC-1 for patients with inflammatory breast carcinoma†
Article first published online: 27 JUL 2004
Copyright © 2004 American Cancer Society
Volume 101, Issue 5, pages 913–917, 1 September 2004
How to Cite
Resetkova, E., Gonzalez-Angulo, A. M., Sneige, N., Mcdonnell, T. J., Buzdar, A. U., Kau, S. W., Yamamura, Y., Reuben, J. M., Hortobagyi, G. N. and Cristofanilli, M. (2004), Prognostic value of P53, MDM-2, and MUC-1 for patients with inflammatory breast carcinoma. Cancer, 101: 913–917. doi: 10.1002/cncr.20465
Presented at the Fifteenth International Congress on Anti-Cancer Treatment, Paris, France, February 9–12, 2004.
Fax: (713) 794-4385
- Issue published online: 18 AUG 2004
- Article first published online: 27 JUL 2004
- Manuscript Revised: 1 JUN 2004
- Manuscript Accepted: 1 JUN 2004
- Manuscript Received: 29 APR 2004
- Nellie B. Connally Breast Cancer Research Fund
- inflammatory breast carcinoma
Inflammatory breast carcinoma (IBC) is a rare and aggressive malignancy. Therapy for patients with IBC is multidisciplinary, and response to preoperative chemotherapy is considered an important predictor of outcome. Although only a limited number of molecular markers have been investigated in this setting, none has exhibited prognostic value for patients with IBC.
Immunohistochemical assays for P53, MDM-2, and MUC-1 were performed retrospectively to evaluate potential correlations between these markers and pathologic response, time to progression (TTP), and overall survival (OS) in 19 patients with IBC.
After a median follow-up period of 46 months, patients with tumors that overexpressed P53 and did not express MUC-1 had a significantly shorter median TTP and median OS compared with other patients.
Expression of P53 and MUC-1 may be predictive of treatment efficacy and outcome for patients with IBC. Furthermore, these two markers may represent novel therapeutic targets in such patients. Cancer 2004. © 2004 American Cancer Society.